Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
by on Monday, January 30th, 2012 | No Comments
Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Intervention: Drug: CPI-613
Sponsor: Cornerstone Pharmaceuticals, Inc.
Not yet recruiting – verified January 2012
Read the original here: Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome